Becton, Dickinson and Co ((BDX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Becton, Dickinson and Co (BDX) is conducting an investigational study titled An Investigational Study to Evaluate the Safety and Performance of the BD PosiFlush™ SafeScrub on Needleless Access Devices. The study aims to assess the safety and effectiveness of the BD PosiFlush™ SafeScrub device in preventing catheter-related bloodstream infections (CRBSI), a significant concern in healthcare settings.
Intervention/Treatment: The study tests the BD PosiFlush™ SafeScrub device, designed to enhance the cleaning of needleless access devices (NADs) to reduce infection risk. The treatment group uses this device, while the control group uses a standard pre-filled saline syringe and alcohol pad.
Study Design: This is a randomized, parallel-assignment study with no masking. Each participating site has a treatment and control arm, focusing on basic science to evaluate the device’s performance in real-world settings.
Study Timeline: The study began on August 21, 2024, with the latest update submitted on August 18, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The successful outcome of this study could positively impact BDX’s stock performance by enhancing its product portfolio and competitive edge in the medical device industry. Investors should monitor this study as it could influence market dynamics and BDX’s positioning against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.